Objective Multiple myeloma (MM) is a highly characteristic tumor that is influenced by
numerous factors that determine its prognosis. Studies indicate that the presence of …

This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and
dexamethasone for induction and consolidation in transplant-eligible patients with newly …

Based on the lack of differences in progression-free and overall survival after a median
follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; n= 395) …

Objectives To evaluate the safety and efficacy of maintenance therapy with the oral
proteasome inhibitor ixazomib in patients with newly diagnosed multiple myeloma (NDMM) …

We analyzed newly diagnosed multiple myeloma patients with del (17p) and/or t (4; 14)
undergoing either upfront single autologous (auto), tandem autologous (auto-auto) or …

Maintenance treatment is a pivotal part in the whole process management of multiple
myeloma (MM), which further deepens response and improves survival. However, evidence …

Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction
therapy (IT), high-dose melphalan (MEL200), and autologous blood stem cell …

Since the introduction of lenalidomide into induction therapy for multiple myeloma (MM),
there have been conflicting reports about its impact on autologous peripheral blood stem …

Recent advances in the treatment of plasma cell disorders (PCDs) have provided a wealth of
therapy alternatives and improved overall survival tremendously. Various types of PCDs are …

The development of new drugs and subsequent novel combinations for the treatment of
newly diagnosed multiple myeloma (NDMM) has resulted in a plethora of treatment options …